Abstract
The purpose of this study was to validate and evaluate the quantification of methylated tumor suppressor genes (TSGs) of plasma in predicting short-term recurrence of surgical patients with NSCLC. Plasma specimens were collected from 54 consecutive NSCLC patients before and after operation, as well as 50 cancer-free controls. All cell-free plasmas were analyzed for the amounts of methylated APC and RASSF1A by duplex real-time methylation-specific PCR. Plasma APC and RASSF1A methylation were correlated to recurrence either before or after operation, but not to age, gender, lymph node invasion, pathologic subtype and grade. The quantities of methylated APC and RASSF1A after operation both presented a similar mode of reduction in non-recurrences and unchanged in recurrences. The plasma methylated RASSF1A was the independent factor related to recurrence after logistic multivariate modeling. The quantification of methylated RASSF1A after operation provides useful prognostic biomarker for predicting recurrence in NSCLC patients after curative-intent surgery.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alberts WM (2007) Follow up and surveillance of the patient with lung cancer: what do you do after surgery? Respirology 12:16–21
Bastian PJ, Palapattu GS, Yegnasubramanian S et al (2007) Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res 13:5361–5367
Beau-Faller M, Gaub MP, Schneider A et al (2003) Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 105:361–370
Carney DN (2002) Lung cancer–time to move on from chemotherapy. N Engl J Med 346:126–128
Esteller M, Sanchez-Cespedes M, Rosell R et al (1999) Detection of aberrant promoter hyper methylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67–70
Fischer JR, Ohnmacht U, Rieger N et al (2007) Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 56:115–123
Fujiwara K, Fujimoto N, Tabata M et al (2005) Identification of epigenetic aberrant promoter methylation in serum DNA Is useful for early detection of lung cancer. Clin Cancer Res 11:1219–1225
Gu J, Berman D, Lu C et al (2006) Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12:7329–7338
Henrique R, Ribeiro FR, Fonseca D et al (2007) High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 13:6122–6129
Herman JG, Graff JR, Myöhänen S et al (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 93:9821–9826
Kim DS, Kim MJ, Lee JY et al (2007) Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer 110:2785–2792
Müller HM, Fiegl H, Widschwendter A et al (2004) Prognostic DNA methylation marker in serum of cancer patients. Ann NY Acad Sci 1022:44–49
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
Safar AM, Spencer H 3rd, Su X et al (2005) Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11:4400–4405
Sozzi G, Conte D, Leon ME et al (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902–3908
Usadel H, Brabender J, Danenberg KD et al (2002) Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62:371–375
Wang Y, Yu Z, Wang T et al (2007) Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 56:289–294
Acknowledgments
We are grateful to the technical support of the Research & Service Center of Cell-free DNA Measurement of China in detecting plasma DNA, the financial support of the National Natural Science Foundation of China (grant no. 30972821), the Natural Science Foundation of Jiangsu Province (grant no. BK2009440), the Key Laboratory for Laboratory Medicine of Jiangsu Province (grant no. XK200731), the project of Health Administration of Jiangsu Province (grant no. H200707) and the project of Jiangsu Science and Technology Department (grant no. BS2007073).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this paper
Cite this paper
Ding, Q. et al. (2010). Plasma DNA Methylation Analysis in Predicting Short-Term Recurrence of Surgical Patients with Non-small Cell Lung Cancer (NSCLC). In: Gahan, P. (eds) Circulating Nucleic Acids in Plasma and Serum. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9382-0_7
Download citation
DOI: https://doi.org/10.1007/978-90-481-9382-0_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9381-3
Online ISBN: 978-90-481-9382-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)